Incyte Corporation (INCY) Actualités

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Incyte présentera de nouvelles données de son portefeuille de dermatologie lors du congrès annuel 2025 de l'Académie américaine de dermatologie (AAD)

- Les résumés pour la crème à base de ruxolitinib (Opzelura®) incluent de multiples présentations sur la dermatite atopique et des données de...

Incyte gibt auf der Jahrestagung der American Academy of Dermatology (AAD) 2025 neue Daten aus seinem Dermatologie-Portfolio bekannt

- Zu den Abstracts für Ruxolitinib-Creme (Opzelura®) gehören mehrere Präsentationen zu atopischer Dermatitis und brandaktuelle Daten zu Prurigo...

Form 4 - Statement of changes in beneficial ownership of securities

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

- Featured abstracts for ruxolitinib cream (Opzelura®) include multiple presentations in atopic dermatitis and late-breaking data in prurigo...

Form 144 - Report of proposed sale of securities

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule...

Incyte to Present at Upcoming Investor Conferences

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen 45th Annual...

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

– Total revenues of $1.2 billion (+16% Y/Y) in the fourth quarter 2024 and $4.2 billion (+15% Y/Y) for the full year 2024 – Jakafi® (ruxolitinib...

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 16,301 shares of the...